Skip to main content
SpringerLink
Log in

A New Microemulsion Formulation of Cyclosporin

Pharmacokinetic and Clinical Features

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Cyclosporin (cyclosporin A) has been used as an immunosuppressive agent after organ transplantation for more than 15 years. The bioavailability of cyclosporin in its conventional oral formulation ‘Sandimmun’ displays considerable inter- and intra-patient variability. Absorption is also bile dependent. Recently, a new galenic formulation of cyclosporin was introduced, ‘Neoral’, which is a water-free microemulsion of cyclosporin. The microemulsion creates micelles which are absorbed in the small bowel without the presence of bile.

Pharmacokinetic studies in healthy volunteers clearly demonstrate an increased bioavailability of the microemulsion formulation of cyclosporin, measured as an increase in maximum drug concentration (Cmax) and area under the drug concentration-time curve, and a reduced time to Cmax. These findings have been confirmed in kidney, liver and heart transplant recipients. With the microemulsion formulation, an improved prediction of cyclosporin concentrations has probably attributed to the decrease found in the variability of cyclosporin absorption. This could probably enable easier and more reliable monitoring of cyclosporin concentrations after transplantation.

So far, data on the effects of conversion from the conventional to the microemulsion formulation of cyclosporin are only available in a limited number of patients and with a limited follow-up period. The main questions are related to what the long term consequences of the improved bioavailability of the microemulsion formulation will be. Further long term studies are needed in order to answer these questions.

In the present review, we report on the pharmacokinetic properties of, and on clinical experience after solid organ and bone marrow transplantation with, the microemulsion formulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Calne RY, White DJG, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; II: 1323–7

    Article  Google Scholar 

  2. McMaster P, Dunn DC, Craddock GN, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs; 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; II: 1033–6

    Google Scholar 

  3. Starzl TE, Weil R III, Iwatsuki S, et al. The use of cyclosporin A and prednisone in cadaveric kidney transplantation. Surg Gynecol Obstetr 1980; 151: 17–26

    CAS  Google Scholar 

  4. Klintmalm GBG, Iwatsuki S, Starzl TE. Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet 1981;I: 470–1

    Article  Google Scholar 

  5. Powles RJ, Clink HM, Spence D. Cyclosporin A to prevent graft-versus-host disease in man after allogenic bone-marrow transplantation. Lancet 1980; 13: 365–7

    Google Scholar 

  6. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporin improves psoriasis in a doubleblind study. JAMA 1986; 256: 3110–6

    Article  PubMed  CAS  Google Scholar 

  7. Tugwell P, Bombardier C, Gent G, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051–5

    Article  PubMed  CAS  Google Scholar 

  8. Feutren G, Mihatsch MJ, the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine-induced nephropathy in patients with auto-immundiseases. New Engl J Med 1992; 326; 1654–60

    Article  PubMed  CAS  Google Scholar 

  9. Mehta M, Venkataramanan R, Buckart GJ. Effects of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol 1984; 25(5): 579–84

    Article  Google Scholar 

  10. Vonderscher J, Meinzer A. Rationale for the development of Sandimmun Neoral. Transplant Proc 1994; 26: 2925–7

    PubMed  CAS  Google Scholar 

  11. Drewe J, Berglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992; 33: 39–43

    Article  PubMed  CAS  Google Scholar 

  12. Friman S, Persson H, Karlberg I, et al. The bile acid independent flow is reduced in the transplanted liver. Transplant Int 1992; 5: S163–S167

    Google Scholar 

  13. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205–18

    Article  PubMed  CAS  Google Scholar 

  14. Ritschel WA, Adolph S, Ritschel GB, et al. Improvement of peroral absorption of cyclosporin A by microemulsions. Meth Find Exp Clin Pharmacol 1990; 12: 127–34

    CAS  Google Scholar 

  15. Levy G, Grant D. Potential for CsA-Neoral in organ transplantation. Transplant Proc 1994; 26: 2932–4

    PubMed  CAS  Google Scholar 

  16. Lin CY, Lee SF. Comparison of pharmacokinetics between CsA capsules and in Sandimmun neoral in pediatric patients. Transplant Proc 1994; 26: 2973–4

    PubMed  CAS  Google Scholar 

  17. Superina RA, Strong DK, Acal LA. Relative bioavailability of Sandimmune and Sandimmune Neoral in pediatric liver recipients. Transplant Proc 1994; 26: 2979–80

    PubMed  CAS  Google Scholar 

  18. Vernillet L, Kovarik JM, Freiburghaus R. Blood cyclosporin A and metabolite kinetic profiles after administration of Sandimmune soft gelatine capsules and Neoral in transplant recipients. Transplant Proc 1994; 26: 2964–8

    PubMed  CAS  Google Scholar 

  19. Trull AK, Tan KKC, Tan L, et al. Absorption of cyclosporin conventional and new microemulsion formulations, in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 1995; 39: 627–31

    Article  PubMed  CAS  Google Scholar 

  20. Drewe J, Meier R, Vonderscher J, et al. Enhancement of the absorption of cyclosporin in man. Br J Clin Pharmacol 1992; 34(1): 60–4

    Article  PubMed  CAS  Google Scholar 

  21. Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from microemulsion formation. Pharm Res 1994; 11: 301–4

    Article  PubMed  CAS  Google Scholar 

  22. Mueller EA, Kovarik JM, van Bree JB, et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporin in a crossover comparison with the market formulation. Pharm Res 1994; 11: 151–5

    Article  PubMed  CAS  Google Scholar 

  23. Browne BJ, Jordan MS, van Buren C, et al. Diet and cyclosporin A — pharmacokinetic comparison between Neoral and Sandimmune gelatin capsules. Transplant Proc 1994; 26: 2959–60

    PubMed  CAS  Google Scholar 

  24. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formation — a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658–63

    PubMed  CAS  Google Scholar 

  25. Kahan BD, Dunn J, Fitts C, et al. The neoral formulation: improved correlation between cyclosporine trough concentrations and exposure in stable renal transplant recipients. Transplant Proc 1994; 26: 2940–3

    PubMed  CAS  Google Scholar 

  26. Mueller EA, Kovarik JM, van Bree JB, et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients — a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57: 1178–82

    Article  PubMed  CAS  Google Scholar 

  27. Foradori AC, Martinez L, Vacarezza A, et al. Pharmacokinetics of a new galenical formulation of oral cyclosporine A in stable kidney transplanted patients. Transplant Proc 1994; 26: 2969–72

    PubMed  CAS  Google Scholar 

  28. Sketris LS, Lawen JG, Beauregard-Zollinger L, et al. Comparison of the pharmacokinetics of cyclosporine Sandimmune with Sandimmune neoral in stable renal transplant patients. Transplant Proc 1994; 26: 2961–3

    PubMed  CAS  Google Scholar 

  29. Kovarik JM, Meuller EA, van Bree JB. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994; 16: 232–7

    Article  PubMed  CAS  Google Scholar 

  30. Kovarik J, Kallay Z, Mueller EA, et al. Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation of stable kidney transplant patients. Transplant Int 1995; 8: 335–9

    Article  CAS  Google Scholar 

  31. Wahlberg J, Wilczek H, Fauchald P, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995; 60: 648–52

    Article  PubMed  CAS  Google Scholar 

  32. Levy G, Rochon J, Freeman D, et al. Cyclosporine neoral liver transplant recipients. Transplant Proc 1994; 26: 2949–52

    PubMed  CAS  Google Scholar 

  33. Mikhail G, Eadon H, Leaver N, et al. Use of neoral in heart transplant recipients. Transplant Proc 1994; 26: 2985–7

    PubMed  CAS  Google Scholar 

  34. Fiocchi R, Mamprin A, Gamba M, et al. Pharmacokinetic profile of cyclosporine in long-term heart transplanted patients treated with a new oral formulation. Transplant Proc 1994; 26: 2994–5

    PubMed  CAS  Google Scholar 

  35. Kovarik JM, Meuller EA, van Bree JB, et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83: 444–6

    Article  PubMed  CAS  Google Scholar 

  36. Keown PA, Stiller CR, Laupacis AL, et al. The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc 1982; 14: 659–61

    PubMed  CAS  Google Scholar 

  37. Keown PA, Stiller CR, Sinclair NR, et al. The clinical relevance of cyclosporine concentrations as measured by radioimmunoassay. Transplant Proc 1983; 15: 2438–41

    Google Scholar 

  38. Ptachinski RJ, Venkataramanan R, Rosenthal JT. The effect of food on cyclosporine absorption. Transplantation 1985; 40: 174–6

    Article  Google Scholar 

  39. Mueller EA, Kovarik JM, Kutz K. Minor influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine. Transplant Proc 1994; 26: 2957–8

    PubMed  CAS  Google Scholar 

  40. Kovarik JM, Mueller EA, Johnston A, et al. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy 1993; 13: 613–7

    PubMed  CAS  Google Scholar 

  41. Kovarik JM, Vaernillet L, Mueller EA, et al. Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation. Ther Drug Monit 1994: 16: 519–25

    Article  PubMed  CAS  Google Scholar 

  42. Taesch S, Niese D. Safety and tolerability of a new oral formulation of cyclosporine A, Sandimmun neoral, in renal transplant patients. Transplant Int 1994; 7Suppl. 1: 263–6

    Article  Google Scholar 

  43. Neumayer HH, Färber L, Haller P, et al. Conversion from Sandimmun to Sandiummun neoral in patients with stable renal allografts: results after 1 month. Transplant Proc 1994; 26: 2944–8

    PubMed  CAS  Google Scholar 

  44. Belli LS, Slim OA, De Carlis L, et al. Neoral liver transplant patients: pharmacokinetic study and clinical implications. Transplant Proc 1994; 26: 2981–2

    PubMed  CAS  Google Scholar 

  45. Atkison PR, Grant DR, Williams SE, et al. Sandimmune neoral in paediatric liver transplant recipients with malabsorption of cyclosporin A. Transplant Proc 1994; 26: 2953–4

    PubMed  CAS  Google Scholar 

  46. Burckart GJ, Venkataramanan R, Ptachinski RJ, et al. Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacol 1986; 26: 647–51

    PubMed  CAS  Google Scholar 

  47. Färber L, Maibücher P, Geissler F, et al. Favourable clinical results of Sandimmun-neoral in malabsorbing liver and heart transplant recipients. Transplant Proc 1994; 26; 2988–93

    PubMed  Google Scholar 

  48. Ferrera G, Fioredda P, Loy A, et al. Oral microemulsion formulation substitutes for intravenous cyclosporin in child with graft-versus-host disease. Lancet 1994; 344: 480–1

    Article  Google Scholar 

  49. Ringden O, Bäckman L, Lönnqvist B, et al. A randomized trial comparing the use of cyclosporin and methotrexate for graft versus host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1986; 1: 41–51

    PubMed  CAS  Google Scholar 

  50. Cockburn ITR, Krupp P. An appraisal of drug interactions with Sandimmun. Transplant Proc 1989; 21: 3845–50

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Transplantation and Liver Surgery, Sahlgrenska University Hospital, S-41345, Gothenburg, Sweden

    Styrbjörn Friman & Lars Bäckman

Authors
  1. Styrbjörn Friman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lars Bäckman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friman, S., Bäckman, L. A New Microemulsion Formulation of Cyclosporin. Clin. Pharmacokinet. 30, 181–193 (1996). https://doi.org/10.2165/00003088-199630030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199630030-00001

Keywords

Search

Navigation